Structural basis for rifamycin resistance of bacterial RNA polymerase by the three most clinically important RpoB mutations found in Mycobacterium tuberculosis.

Abstract excerpt

Since 1967, Rifampin (RMP, a Rifamycin) has been used as a first line antibiotic treatment for tuberculosis (TB), and it remains the cornerstone of current short-term TB treatment. Increased occurrence of Rifamycin-resistant (RIFR ) TB, ∼41% of which results from the RpoB S531L mutation in RNA polymerase (RNAP), has become a growing problem worldwide. In this study, we determined the X-ray crystal structures of...

Topics

Join the communities discussing this publication.

• Antibiotics, Antitubercular
• Crystallography, X-Ray
• DNA-Directed RNA Polymerases
• Drug Resistance, Bacterial
• Mycobacterium tuberculosis